Albion Financial Group UT raised its position in shares of The Clorox Company (NYSE:CLX - Free Report) by 8.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,774 shares of the company's stock after purchasing an additional 2,669 shares during the period. Albion Financial Group UT's holdings in Clorox were worth $5,121,000 at the end of the most recent reporting period.
Other institutional investors have also added to or reduced their stakes in the company. Redwood Park Advisors LLC bought a new position in shares of Clorox in the 4th quarter valued at $26,000. Millstone Evans Group LLC acquired a new stake in Clorox in the fourth quarter valued at about $31,000. Wood Tarver Financial Group LLC bought a new position in Clorox in the fourth quarter valued at about $31,000. GKV Capital Management Co. Inc. acquired a new position in Clorox during the fourth quarter worth about $32,000. Finally, Aster Capital Management DIFC Ltd bought a new position in shares of Clorox in the fourth quarter worth about $33,000. 78.53% of the stock is currently owned by institutional investors and hedge funds.
Clorox Trading Up 0.1%
CLX traded up $0.14 during midday trading on Thursday, hitting $124.80. 1,078,076 shares of the company were exchanged, compared to its average volume of 1,397,254. The firm's 50 day moving average price is $130.17 and its 200-day moving average price is $144.40. The Clorox Company has a 1-year low of $117.35 and a 1-year high of $171.37. The firm has a market capitalization of $15.38 billion, a P/E ratio of 22.41, a P/E/G ratio of 3.01 and a beta of 0.51. The company has a quick ratio of 0.44, a current ratio of 0.74 and a debt-to-equity ratio of 13.07.
Clorox (NYSE:CLX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported $1.45 EPS for the quarter, missing analysts' consensus estimates of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to analyst estimates of $1.74 billion. Clorox had a return on equity of 324.23% and a net margin of 9.89%. Clorox's revenue was down 8.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.71 earnings per share. As a group, equities analysts forecast that The Clorox Company will post 7.15 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
CLX has been the topic of several research reports. Citigroup decreased their price target on shares of Clorox from $165.00 to $150.00 and set a "neutral" rating on the stock in a report on Monday, April 14th. UBS Group decreased their target price on shares of Clorox from $176.00 to $154.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. Morgan Stanley lowered their price target on shares of Clorox from $165.00 to $150.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Evercore ISI set a $140.00 price objective on Clorox and gave the company an "underperform" rating in a report on Tuesday, May 6th. Finally, JPMorgan Chase & Co. lowered their target price on Clorox from $151.00 to $144.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Three research analysts have rated the stock with a sell rating, ten have assigned a hold rating and one has given a buy rating to the stock. According to MarketBeat.com, Clorox presently has a consensus rating of "Hold" and a consensus price target of $149.50.
Get Our Latest Research Report on Clorox
Insider Activity at Clorox
In other news, Director Pierre R. Breber acquired 4,000 shares of the firm's stock in a transaction dated Wednesday, May 7th. The stock was bought at an average cost of $136.57 per share, for a total transaction of $546,280.00. Following the completion of the transaction, the director directly owned 4,000 shares in the company, valued at $546,280. This represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.57% of the company's stock.
Clorox Company Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
Further Reading

Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.